Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

Researchers reverse Alzheimers memory loss in mice

Researchers reverse Alzheimer’s memory loss in mice

The Buffalo researchers believe their work in the developing science of epigenetics will yield answers in the elusive search for new Alzheimer's therapies. ... Meanwhile, the next big hope in the pharma industry’s late stage pipeline for Alzheimer’s

Latest news

  • Rising economic risk casts shadow on Davos meeting Rising economic risk casts shadow on Davos meeting

    Brazil's new right-wing president Jair Bolsonaro. Other absentees include the prime ministers of Canada and India, Justin Trudeau and Narendra Modi. ... The gathering's 350 sessions will cover other health issues including the growing global mental

  • Pfizer takeover rumour ignites Amarin shares Pfizer takeover rumour ignites Amarin shares

    Shire acquisition and Bristol-Myers Squibb’s $74bn Celgene takeover, after failing to reach terms with AstraZeneca a few years ago. ... Analysts are now betting that Biogen could be the next company to announce a deal, as it is becoming increasingly

  • Lilly partners with AC Immune on tau drug for Alzheimer’s Lilly partners with AC Immune on tau drug for Alzheimers

    Potential payments of $1.7bn to Swiss firm. Eli Lilly has had no luck when it comes to developing Alzheimer’s disease (AD) drugs, but it’s not giving up – spending ... CHF 80m ($81m) upfront to license a tau-targeting candidate from Switzerland’s

  • Axovant drops last ‘legacy’ drug to focus on gene therapies Axovant drops last ‘legacy’ drug to focus on gene therapies

    The decision to scrap nelotanserin comes after Axovant’s Alzheimer’s disease candidate intepirdine joined the chorus of failed drug candidates in that indication, and draws a line under the ... s original business model of licensing dormant drugs

  • US ‘unicorn’ Samumed on track with lead arthritis drug US ‘unicorn’ Samumed on track with lead arthritis drug

    Samumed will showcase another of its pipeline drugs this week at the Clinical Trials on Alzheimer’s Disease (CTAD) Congress, which started in Barcelona yesterday. ... Preclinical data on DYRK1A inhibitor SM07883, which the company says is a potential

More from news
Approximately 89 fully matching, plus 373 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimers disease – is Europe prepared if a breakthrough treatment becomes available?

    Currently, there is no Alzheimer’s disease- modifying treatment available but there are several therapies in development. ... In France, 389, 000 people might develop Alzheimer’s dementia while waiting for evaluation and treatment.

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    ‘Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development’. ... The design of such neuroprotective studies may benefit from the lessons learned in studies in the most common neurodegenerative disease, Alzheimer’s.

  • Tackling a formidable foe Tackling a formidable foe

    MAVENCLAD’S short-course oral therapy profile is a bonus to a condition freighted with psychological drag-weights. ... s or Alzheimer’s.

  • What can pharma learn from the charity sector? What can pharma learn from the charity sector?

    the charity sector (or third sector, as it’s also known) to better support its patients. ... Dr Doug Brown, Chief Policy and Research Officer at Alzheimer’s Society, explains how co-creation is an essential part of its research process:.

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... Collaboration, licence. 830. Molecular

More from intelligence
Approximately 2 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest from PMHub

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases. ... Please contact us at info@random42.com to arrange a meeting. For more information on Random42’s capabilities please see

  • The dark side of direct-to-consumer genetic tests

    Who can blame them? If an email landed in your inbox that appeared to indicate you had an increased risk of cancer, Parkinson’s disease, Alzheimer’s disease, or any other

  • Attigo (part of the Mednet Group)

    Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK. ... Mednet Group's white paper with a focus on navigating the world of work is available online in aid of World Mental Health Day 2018.

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    the US suffer from Alzheimer’s disease, and  795, 000  Americans suffer from strokes annually. ... It’s a little bit like it was in the old days of buying IBM computers,” he says.

  • Synergy Vision

    Alzheimer's and Brain Awareness Month. ... June 2017 is Alzheimer’s and Brain Awareness Month, which aims to raise awareness about Alzheimer’s disease (AD) and other types of dementia.

More from PMHub
Approximately 3 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics